Get the Stockscreener App
15.31
1.10%
-0.17
After Hours:
15.31
Takeda Pharmaceutical Co Adr stock is traded at $15.31, with a volume of 3.39M.
It is down -1.10% in the last 24 hours and up +6.02% over the past month.
Takeda Pharmaceutical is Japan's largest pharmaceutical company, with revenue of JPY 4.6 trillion in fiscal 2024. The company's five core therapeutic areas are oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies, which account for more than 80% of revenue. Its geographic footprint is well diversified, with over 50% derived from the US, 20% from Japan, 20% from Europe and Canada.
See More
Previous Close:
$15.48
Open:
$15.27
24h Volume:
3.39M
Relative Volume:
1.06
Market Cap:
$48.72B
Revenue:
$29.96B
Net Income/Loss:
$957.25M
P/E Ratio:
50.36
EPS:
0.304
Net Cash Flow:
$4.77B
1W Performance:
+3.45%
1M Performance:
+6.02%
6M Performance:
+8.89%
1Y Performance:
+2.48%
1-Day Range:
$15.27
$15.35
1-Week Range:
$14.88
$15.55
52-Week Range:
$12.80
$15.55
Takeda Pharmaceutical Co Adr Stock (TAK) Company Profile
Compare TAK with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TAK
Takeda Pharmaceutical Co Adr
|
15.31 | 47.88B | 29.96B | 957.25M | 4.77B | 0.304 |
|
ZTS
Zoetis Inc
|
155.61 | 67.51B | 9.39B | 2.62B | 2.22B | 5.81 |
|
HLN
Haleon Plc Adr
|
9.81 | 43.42B | 14.26B | 1.98B | 2.47B | 0.4347 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
18.80 | 20.72B | 16.70B | -157.13M | 1.19B | -0.155 |
|
UTHR
United Therapeutics Corp
|
310.66 | 14.21B | 2.99B | 1.21B | 1.13B | 25.06 |
Takeda Pharmaceutical Co Adr Stock (TAK) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-02-25 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Mar-16-23 | Upgrade | BofA Securities | Neutral → Buy |
| Jul-19-22 | Upgrade | Cowen | Market Perform → Outperform |
| Oct-07-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Apr-19-21 | Downgrade | JP Morgan | Overweight → Neutral |
| Nov-01-19 | Initiated | Cowen | Market Perform |
| Aug-15-19 | Downgrade | Daiwa Securities | Outperform → Neutral |
View All
Takeda Pharmaceutical Co Adr Stock (TAK) Latest News
Ascentage Pharma Reports 2025 Interim Unaudited Six Months Financial Results and Business Updates - GlobeNewswire Inc.
TAK’s Market Quandary: Decoding the Ups and Downs of 2025 - investchronicle.com
Blair William & Co. IL Cuts Stock Position in Takeda Pharmaceutical Co. (NYSE:TAK) - Defense World
Takeda Pharmaceutical Co ADR (TAK) Stock: A Year of Stock Market Dynamics - investchronicle.com
Asian ADRs Fall As Winners And Losers Stand Out - Finimize
The 30-day ADR trend, in yen terms, shows high values for Keyence, Kyocera Corporation Sponsored ADR, and Murata Manufacturing. - 富途牛牛
Takeda Pharma ADR earnings beat by $150.82, revenue fell short of estimates - Investing.com UK
On the 21st, ADR movements in yen terms showed high values for NISSAN MOTOR CO LTD, NINTENDO CO LTD, and Sumitomo Trust. - 富途牛牛
Why This Biotech's Dive Benefits Its Top Three Rivals - Investor's Business Daily
Takeda: Positioned To Tackle Future Clinical Demand In A Highly Regulated Sector (TAK) - Seeking Alpha
Behind Takeda Pharmaceutical Co ADR’s 52-Week Range: Uncovering Opportunities for Investors - investchronicle.com
Takeda stock rises after positive Phase 3 results for narcolepsy drug - Investing.com
Takeda stock rises after positive Phase 3 results for narcolepsy drug By Investing.com - Investing.com South Africa
Haleon PLC Sponsored ADR (NYSE:HLN) Shares Purchased by Allspring Global Investments Holdings LLC - Defense World
Takeda Pharmaceutical ADR Earns RS Rating Upgrade - MSN
Nomura Holdings Inc ADR (NYSE:NMR) Shares Acquired by GAMMA Investing LLC - Defense World
Hengan International Group (OTCMKTS:HEGIY) Stock Price Up 3.7% – Time to Buy? - Defense World
Expedia Group Earns RS Rating Upgrade - inkl
GAMMAGARD LIQUID ERC, GAMMAGARD LIQUID and GAMMAGARD S/D U.S. Important Safety Information - Placera.se
Stocks With Rising Relative Price Strength: IREN - inkl
Stocks With Rising Relative Strength: Dr. Reddy's Labs ADR - inkl
Nano Dimension Ltd ADR’s Shares Reel: -28.07% Quarterly Revenue Decline Amid 329.06M Market Cap - investchronicle.com
MNST’s Stock Market Adventure: 19.08% YTD Growth Amidst Volatility - investchronicle.com
On the 10th, the ADR trends show that Takeda Pharmaceutical, Nidec Corporation Sponsored ADR, Advantest, and others are performing well in terms of yen conversion. - 富途牛牛
SEC Form N-CSRS filed by abrdn World Healthcare Fund Shares of Beneficial Interest - Quantisnow
EU approves Takeda’s new Hodgkin lymphoma treatment - Investing.com
IgA nephropathy Pipeline Drugs Analysis 2025: Clinical Trials, - openPR.com
CTVA’s Stock Market Adventure: 22.38% YTD Growth Amidst Volatility - investchronicle.com
Takeda files executive compensation report with SEC - Investing.com
Cameco Earns Relative Strength Rating Upgrade; Hits Key Threshold - inkl
TD Cowen maintains Buy on Takeda, reiterates $16 target - Investing.com
Stocks With Rising Relative Strength: Novartis ADR - inkl
Fidelity Natl Info Svcs Shows Rising Relative Strength; Still Shy Of Key Benchmark - inkl
Real-World Effectiveness and Safety of Vedolizumab in Patients ≥ 70 Versus - Wiley Online Library
Weekly Stock Grader Analysis: Upgrades & Downgrades on Top Blue-Chip Stocks - InvestorPlace
Financial Metrics Unveiled: Topgolf Callaway Brands Corp (MODG)’s Key Ratios in the Spotlight - DWinneX
Ratios Reveal: Breaking Down Takeda Pharmaceutical Co ADR (TAK)’s Financial Health - DWinneX
Balance Sheet Insights: Nuveen Churchill Direct Lending Corp (NCDL)’s Debt-to-Equity and Long-Term Debt/Eq Ratios - DWinneX
Takeda continues stock plan for management in 2025 - Investing.com
Novavax revises Takeda deal for Japan vaccine sales - Investing.com
TAK or DSNKY: Which Is the Better Value Stock Right Now? - Yahoo Finance
Taking a look at what insiders are doing to gauge the Takeda Pharmaceutical Co ADR (TAK)’s direction - knoxdaily.com
Takeda Pharmaceutical Co ADR [TAK] Insider Activity: An Update for Investors - knoxdaily.com
Exelixis' Q1 Earnings: Will Cabometyx Maintain Momentum? - Yahoo Finance
A significant driver of top-line growth: Takeda Pharmaceutical Co ADR (TAK) - Sete News
Nothing is Better Than C.H. Robinson Worldwide, Inc (CHRW) stock at the moment - Sete News
Takeda Pharmaceutical Co ADR Inc. (TAK) Price Performance: A Comparative Analysis with Competitors - investchronicle.com
Carmax Inc: Analyzing KMX Stock Trends - investchronicle.com
Takeda Pharmaceutical Co Adr Stock (TAK) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.01%
6.76%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):